Cargando…
Astragaloside IV, as a potential anticancer agent
Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated mode...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981805/ https://www.ncbi.nlm.nih.gov/pubmed/36874003 http://dx.doi.org/10.3389/fphar.2023.1065505 |
_version_ | 1784900188465266688 |
---|---|
author | Xia, Dongqin Li, Wenjie Tang, Ce Jiang, Juan |
author_facet | Xia, Dongqin Li, Wenjie Tang, Ce Jiang, Juan |
author_sort | Xia, Dongqin |
collection | PubMed |
description | Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of Astragalus membranaceus. AS-IV exhibits various pharmacological effects, such as anti-inflammatory, hypoglycemic, antifibrotic, and anticancer activities. AS-IV possesses a wide range of activities, such as the modulation of reactive oxygen species-scavenging enzyme activities, participation in cell cycle arrest, induction of apoptosis and autophagy, and suppression of cancer cell proliferation, invasiveness, and metastasis. These effects are involved in the inhibition of different malignant tumors, such as lung, liver, breast, and gastric cancers. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research of this TCM. |
format | Online Article Text |
id | pubmed-9981805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99818052023-03-04 Astragaloside IV, as a potential anticancer agent Xia, Dongqin Li, Wenjie Tang, Ce Jiang, Juan Front Pharmacol Pharmacology Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of Astragalus membranaceus. AS-IV exhibits various pharmacological effects, such as anti-inflammatory, hypoglycemic, antifibrotic, and anticancer activities. AS-IV possesses a wide range of activities, such as the modulation of reactive oxygen species-scavenging enzyme activities, participation in cell cycle arrest, induction of apoptosis and autophagy, and suppression of cancer cell proliferation, invasiveness, and metastasis. These effects are involved in the inhibition of different malignant tumors, such as lung, liver, breast, and gastric cancers. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research of this TCM. Frontiers Media S.A. 2023-02-17 /pmc/articles/PMC9981805/ /pubmed/36874003 http://dx.doi.org/10.3389/fphar.2023.1065505 Text en Copyright © 2023 Xia, Li, Tang and Jiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Xia, Dongqin Li, Wenjie Tang, Ce Jiang, Juan Astragaloside IV, as a potential anticancer agent |
title | Astragaloside IV, as a potential anticancer agent |
title_full | Astragaloside IV, as a potential anticancer agent |
title_fullStr | Astragaloside IV, as a potential anticancer agent |
title_full_unstemmed | Astragaloside IV, as a potential anticancer agent |
title_short | Astragaloside IV, as a potential anticancer agent |
title_sort | astragaloside iv, as a potential anticancer agent |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981805/ https://www.ncbi.nlm.nih.gov/pubmed/36874003 http://dx.doi.org/10.3389/fphar.2023.1065505 |
work_keys_str_mv | AT xiadongqin astragalosideivasapotentialanticanceragent AT liwenjie astragalosideivasapotentialanticanceragent AT tangce astragalosideivasapotentialanticanceragent AT jiangjuan astragalosideivasapotentialanticanceragent |